Latest News in the pharma Industry

Research & Development

Inovio HIV vaccine elicits nearly 100% immune response rates in a clinical study

Inovio HIV vaccine elicits nearly 100% immune response rates in a clinical study

26 May 2017

Amongst highest levels of immune responses ever demonstrated in an HIV vaccine human study.

Read more 
Hovione starts clinical trial of its proprietary minocycline sterile ointment to treat a subset of anterior ocular inflammation

Hovione starts clinical trial of its proprietary minocycline sterile ointment to treat a subset of anterior ocular inflammation

25 May 2017

First clinical study using a patent protected minocycline API and formulation developed by Hovione.

Read more 
IPF patients treated with Ofev vs placebo twice as likely to have improved or stable lung function

IPF patients treated with Ofev vs placebo twice as likely to have improved or stable lung function

25 May 2017

Separate subgroup analysis demonstrates long-term efficacy of Ofev in slowing disease progression is maintained for up to 96 weeks in IPF patients who require dose adjustments to manage adverse events.

Read more 
New analyses reinforce the potential of Ultibro Breezhaler for COPD patients historically treated with steroids

New analyses reinforce the potential of Ultibro Breezhaler for COPD patients historically treated with steroids

23 May 2017

New analyses from the FLAME study suggest dual bronchodilator Ultibro Breezhaler provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil counts.

Read more 
Spiriva Respimat inhalation spray improves breathing for people with asthma regardless of BMI or allergic status

Spiriva Respimat inhalation spray improves breathing for people with asthma regardless of BMI or allergic status

23 May 2017

In all analyses, people experiencing uncontrolled asthma symptoms saw improvements in their breathing by adding Spiriva Respimat to an ICS or combination ICS/LABA.

Read more 
FDA approves Genentech’s Actemra for giant cell arteritis

FDA approves Genentech’s Actemra for giant cell arteritis

22 May 2017

Sixth FDA approval for Actemra since its US launch in 2010,

Read more 
Catalent and Therachon to advance clinical development of innovative protein therapy for achondroplasia

Catalent and Therachon to advance clinical development of innovative protein therapy for achondroplasia

15 May 2017

Catalent Biologics will use its proprietary GPEx technology to produce different protein variants for Therachon,

Read more 
Positive results for Lilly's three Phase III studies of galcanezumab for the prevention of migraine

Positive results for Lilly's three Phase III studies of galcanezumab for the prevention of migraine

14 May 2017

Read more 
Genentech to present new data on personalized medicines and cancer immunotherapies

Genentech to present new data on personalized medicines and cancer immunotherapies

12 May 2017

New pivotal results for Perjeta and Alecensa demonstrating improvement over standards of care.

Read more 
Avastin as effective as Eylea for treating central retinal vein occlusion

Avastin as effective as Eylea for treating central retinal vein occlusion

12 May 2017

NIH-funded clinical trial shows use of either drug improved vision and had few side effects.

Read more 
Merck's Keytruda scores another FDA approval

Merck's Keytruda scores another FDA approval

11 May 2017

FDA approves Keytruda as first-line combination therapy with pemetrexed and carboplatin for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression.

Read more 
Roche's Tecentriq flops during Phase III trial

Roche's Tecentriq flops during Phase III trial

10 May 2017

IMvigor211 failed to meet its primary endpoint of overall survival (OS) compared with chemotherapy.

Read more